RE:RE:Newbies I am your George Ball.....This from the partnership entry on Adlai Nortye's website.
“Adlai Nortye has a top-tier clinical, regulatory and commercial team with global experience, that will be able to gain significant regional exposure for REOLYSIN upon potential approval, following our phase 3 study in HR+/HER2- static breast cancer,” said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. “China is the fastest growing pharmaceutical market in the world, and we are delighted to be able to unlock value for Oncolytics and our shareholders through this regional partnership. We’re very happy this was able to happen as expediently as it did following our end-of-phase two meeting with the FDA. On the back of that meeting we also have escalated our efforts to find a suitable global or larger regional partner, in regions such as Europe or Japan, and look forward to providing updates on our progress in the first half of 2018.”
So, it's now more than 5 years since ONCY signed AN as a partner... They don't mention Pelareorep in any of their pipeline slides. Does anyone wonder why that is ?
ONCY had a green light to begin a Phase III on the strength of IND-213. It would almost be complete by now,. but they could not find a partner willing to fund it... but why not, they only had to repeat the success seen in IND-213 to be certain of approval... The FDA even granted them Fast Track access... People, stop and think... WHAT is wrong with this picture... Read Matt's statement above from 2017 - in 5 years they still couldn't find a partner, and Canadafan wants you to believe this company will be bought out for billions.
Is it worth risking your hard earned money here... honestly, please look at the history of missed timelines, stock pumping and 100% price collapse after news... this company needs to raise cash, to stay in the game, that means much more dilution at this price... potential buyers know this... they only have to wait like circling vultures... GLTA